MedTrace Logo

Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)

NCT01138618 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 85

Last updated 2011-11-07

No results posted yet for this study

Summary

Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine

Conditions

Interventions

DEVICE

Venous blod sample

Regular venous blood sample withdrawn from the laboratory

DEVICE

CHEMPAQ

Capillary blood sample analyzed by CHEMPAQ

Sponsors & Collaborators

  • Aalborg Psychiatric Hospital

    collaborator OTHER

  • University of Aarhus

    lead OTHER

Principal Investigators

  • Jimmi Nielsen, MD · Aalborg Psychiatric Hospital, Aarhus University Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-12-31
Completion
2011-05-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01138618 on ClinicalTrials.gov